베라사이트 (VCYT) 주가

베라사이트(VCYT)는 NASDAQ에 상장된 Healthcare · Diagnostics & Research 기업입니다. 현재가 $41.25 (-3.17%), 시가총액 $3.33B, PER 38.60, 52주 범위 $23.03 ~ $49.38.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

핵심 지표

• 현재가: $41.25 (-3.17%)
• 시가총액: $3.33B
• PER (주가수익비율): 38.60
• 52주 최저~최고: $23.03 ~ $49.38
• 섹터: Healthcare
• 산업: Diagnostics & Research
• 거래소: NASDAQ

베라사이트의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

베라사이트 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.2727

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.46
• 순이익률: 0.16%
• 영업이익률: 0.16%

자주 묻는 질문